Clinical and Technical Considerations for Brain PET Imaging for Dementia

被引:3
|
作者
Acuff, Shelley N. [1 ]
Mathotaarachchi, Sulantha [2 ]
Zukotynski, Katherine [3 ,4 ,5 ]
Osborne, Dustin [1 ]
Subramaniam, Rathan [5 ]
机构
[1] Univ Tennessee, Grad Sch Med, Dept Radiol, Med Ctr, Knoxville, TN 37920 USA
[2] McGill Univ, Res Ctr Studies Aging, Montreal, PQ, Canada
[3] McMaster Univ, Dept Med, Hamilton, ON, Canada
[4] McMaster Univ, Dept Radiol, Hamilton, ON, Canada
[5] Univ Texas Southwestern Med Ctr Dallas, Harold Simmons Comprehens Canc Ctr, Dept Radiol, Div Nucl Med, Dallas, TX 75390 USA
基金
美国国家卫生研究院; 加拿大健康研究院;
关键词
brain; PET; amyloid; tau; TAU; DIAGNOSIS;
D O I
10.2967/jnmt.118.220087
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The number of cases of dementia has dramatically increased over the last decade. Imaging of the brain with PET has been used for many years, but in the past decade the radiopharmaceuticals and technology available for imaging dementia have vastly improved. In recent years, the U.S. Food and Drug Administration has approved 3 PET radiopharmaceuticals for detecting amyloid in brain, and tau PET radiopharmaceuticals are being investigated in clinical trials for use in dementia imaging. This paper will discuss different forms of dementia that can be imaged with PET, review common radiopharmaceuticals used for imaging dementia, and provide technical recommendations for performing the studies.
引用
收藏
页码:5 / 8
页数:4
相关论文
共 50 条
  • [21] Technical considerations and potential clinical advantages of musculoskeletal imaging at 3.0 Tesla
    Gandhi, Ripal T.
    Kuo, Raymond
    Crues, John V., III
    SEMINARS IN MUSCULOSKELETAL RADIOLOGY, 2008, 12 (03) : 185 - 195
  • [22] Pacing in magnetic resonance imaging environment:: Clinical and technical considerations on compatibility
    Duru, F
    Luechinger, R
    Scheidegger, MB
    Lüscher, TF
    Boesiger, P
    Candinas, R
    EUROPEAN HEART JOURNAL, 2001, 22 (02) : 113 - 124
  • [23] Clinical evaluation of automated parametric imaging for FDG brain PET imaging
    Kemp, Brad
    Schumacher, Michael
    Jordan, Lennon
    Ashrafinia, Saeed
    Smith, Anne
    Lowe, Val
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62
  • [24] What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?
    Jagust, W.
    Reed, B.
    Mungas, D.
    Ellis, W.
    DeCarli, C.
    NEUROLOGY, 2007, 69 (09) : 871 - 877
  • [25] Clinical diagnosis, FDG-PET imaging and pathological outcomes in dementia
    Jagust, William J.
    Reed, Bruce
    Mungas, Dan
    Ellis, William
    DeCarli, Charles
    NEUROLOGY, 2007, 68 (12) : A59 - A59
  • [26] PET imaging for addiction medicine: From neural mechanisms to clinical considerations
    Wiers, Corinde E.
    Cabrera, Elizabeth
    Skarda, Emily
    Volkow, Nora D.
    Wang, Gene-Jack
    NEUROSCIENCE FOR ADDICTION MEDICINE: FROM PREVENTION TO REHABILITATION - METHODS AND INTERVENTIONS, 2016, 224 : 175 - 201
  • [27] Metformin and cancer: Technical and clinical implications for FDG-PET imaging
    Capitanio, Selene
    Marini, Cecilia
    Sambuceti, Gianmario
    Morbelli, Silvia
    WORLD JOURNAL OF RADIOLOGY, 2015, 7 (03): : 57 - 60
  • [28] Is there a preference for PET or SPECT brain imaging in diagnosing dementia? The views of people with dementia, carers, and healthy controls
    Bamford, Claire
    Olsen, Kirsty
    Davison, Chris
    Barnett, Nicky
    Lloyd, Jim
    Williams, David
    Firbank, Michael
    Mason, Helen
    Donaldson, Cam
    O'Brien, John
    INTERNATIONAL PSYCHOGERIATRICS, 2016, 28 (01) : 123 - 131
  • [29] Brain imaging in dementia
    Filippi, M.
    JOURNAL OF NEUROLOGY, 2006, 253 : 5 - 5
  • [30] Brain imaging in dementia
    Bonifacio, Guendalina
    Zamboni, Giovanna
    POSTGRADUATE MEDICAL JOURNAL, 2016, 92 (1088) : 333 - 340